Editor's Preface | p. ix |
Preface | p. xi |
Acknowledgments | p. xiii |
Introduction | p. 1 |
Basic Principles | p. 3 |
The Anatomy of the Prostate Gland | p. 3 |
Function of the Prostate Gland | p. 5 |
Epidemiology of Prostate Cancer | p. 5 |
Prevention of Prostate Cancer | p. 9 |
Prostate Cancer Screening | p. 11 |
Prostate Cancer Clinical States and Transitions | p. 15 |
References | p. 16 |
Clinical State: No Cancer Diagnosis | p. 19 |
The Diagnosis of Prostate Cancer | p. 21 |
Introduction | p. 21 |
History | p. 21 |
General Physical Examination | p. 23 |
Digital Rectal Examination (DRE) | p. 23 |
PSA | p. 25 |
New Serological Tests for Prostate Cancer | p. 31 |
Transrectal Ultrasonography (TRUS) | p. 31 |
Indications for TRUS-Guided Biopsy | p. 31 |
TRUS-Guided Biopsy | p. 32 |
TRUS Biopsy-Sampling | p. 33 |
Repeat Prostate Biopsy | p. 34 |
ASAP | p. 35 |
High-Grade PIN (HGPIN) | p. 35 |
Summary | p. 36 |
References | p. 36 |
Pathology of Prostate Cancer | p. 39 |
Histologic Types | p. 39 |
Tumor Grade (Adenocarcinoma) | p. 41 |
Additional Pathologic Findings | p. 42 |
Role of Pathology in Prostate Cancer Risk Assessment | p. 44 |
References | p. 44 |
Clinical State: Localized Disease | p. 45 |
Staging and Risk Assessment | p. 47 |
Introduction | p. 47 |
Staging | p. 48 |
Risk Assessment | p. 56 |
References | p. 60 |
Primary Management of Favorable- and Intermediate-Risk Prostate Cancer | p. 63 |
Introduction | p. 63 |
The Initial Management Consultation | p. 64 |
Surgical Approaches to Clinically Localized Prostate Cancer | p. 64 |
External-Beam Radiotherapy (EBRT) | p. 79 |
Brachytherapy | p. 89 |
EBRT Plus Brachytherapy | p. 95 |
High Dose Rate (HDR) Temporary Brachytherapy | p. 97 |
Miscellaneous Nonsurgical Approaches to Localized Prostate Cancer | p. 96 |
Noncurative Approaches to Localized Prostate Cancer | p. 97 |
Low- and Intermediate-Risk Prostate Cancer Primary Management Summary | p. 102 |
References | p. 104 |
Management of High-Risk Prostate Cancer-Adjuvant and Neoadjuvant Strategies | p. 111 |
Introduction | p. 111 |
Definition | p. 111 |
Adjuvant/Neoadjuvant Strategies for Patients Undergoing Surgical Prostatectomy | p. 113 |
Neoadjuvant Hormone Therapy Prior to Prostatectomy | p. 113 |
Neoadjuvant Chemotherapy Prior to Prostatectomy | p. 114 |
Adjuvant Chemotherapy After Prostatectomy | p. 115 |
Adjuvant Hormone Therapy After Prostatectomy | p. 116 |
Adjuvant Radiotherapy After Prostatectomy | p. 117 |
Neoadjuvant/Adjuvant Strategies for Patients Undergoing Radiotherapy | p. 119 |
Neoadjuvant Chemotherapy Prior to Radiotherapy | p. 119 |
Neoadjuvant or Adjuvant Hormone Therapy and Radiotherapy | p. 119 |
Summary and Conclusions Regarding Adjuvant/Neoadjuvant Therapy | p. 126 |
References | p. 127 |
Clinical State: Rising PSA | p. 131 |
Biochemical Failure and Salvage Therapy | p. 133 |
Introduction | p. 133 |
Summary and Conclusions, Biochemical Relapse and Salvage Therapy | p. 145 |
References | p. 147 |
Clinical States: Castrate and Noncastrate Metastatic Disease | p. 149 |
Hormone Therapy of Prostate Cancer | p. 151 |
Introduction | p. 151 |
Background | p. 151 |
Controversies in Hormone Therapy | p. 164 |
Complications of ADT | p. 168 |
Summary and Practical Use of ADT | p. 172 |
The Transition to the Castrate Metastatic State | p. 174 |
References | p. 174 |
Treatment of Castrate Metastatic Prostate Cancer (CMPC) | p. 179 |
Introduction | p. 179 |
Definition of Castrate Metastatic State | p. 179 |
Chemotherapy | p. 180 |
High-Grade Tumors and Unusual Histologic Forms | p. 191 |
Additional Approaches to Patients with CMPC | p. 191 |
Palliative EBRT | p. 194 |
Systemic Radiopharmaceuticals | p. 196 |
Surgery | p. 198 |
Nonspecific Measures | p. 198 |
Treatment of General Symptoms of Advanced CMPC | p. 198 |
Investigational Therapy | p. 200 |
Complementary Therapy for Prostate Cancer | p. 204 |
Summary and Conclusions, Treatment of CMPC | p. 205 |
References | p. 206 |
Selected Complications of Advanced Prostate Cancer | p. 213 |
Introduction | p. 213 |
Neuropsychiatric Complications | p. 213 |
Hematologic Complications | p. 221 |
Renal and Urologic Complications | p. 226 |
Metaholic/Endocrine Complications-Hypocalcemia | p. 230 |
Vascular Complications of Prostate Cancer | p. 231 |
References | p. 232 |
Index | p. 235 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.